Your browser doesn't support javascript.
loading
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock, Julio; Wysham, Carol; Frías, Juan P; Kaneko, Shizuka; Lee, Clare J; Fernández Landó, Laura; Mao, Huzhang; Cui, Xuewei; Karanikas, Chrisanthi A; Thieu, Vivian T.
Affiliation
  • Rosenstock J; Dallas Diabetes Research Center at Medical City, Dallas, TX, USA. Electronic address: juliorosenstock@dallasdiabetes.com.
  • Wysham C; MultiCare Rockwood Clinic, Spokane, WA, USA.
  • Frías JP; National Research Institute, Los Angeles, CA, USA.
  • Kaneko S; Takatsuki Red Cross Hospital, Osaka, Japan.
  • Lee CJ; Eli Lilly and Company, Indianapolis, IN, USA.
  • Fernández Landó L; Eli Lilly and Company, Indianapolis, IN, USA.
  • Mao H; Eli Lilly and Company, Indianapolis, IN, USA.
  • Cui X; Eli Lilly and Company, Indianapolis, IN, USA.
  • Karanikas CA; Eli Lilly and Company, Indianapolis, IN, USA.
  • Thieu VT; Eli Lilly and Company, Indianapolis, IN, USA.
Lancet ; 398(10295): 143-155, 2021 07 10.
Article in En | MEDLINE | ID: mdl-34186022

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastric Inhibitory Polypeptide / Double-Blind Method / Diabetes Mellitus, Type 2 / Hypoglycemic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Asia Language: En Journal: Lancet Year: 2021 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastric Inhibitory Polypeptide / Double-Blind Method / Diabetes Mellitus, Type 2 / Hypoglycemic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Asia Language: En Journal: Lancet Year: 2021 Document type: Article Country of publication: United kingdom